Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

GLENMARK's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 1.558000
forwardPE 19.491821
debtToEquity 27.943000
earningsGrowth 0.000000
revenueGrowth -0.161000
grossMargins 0.675980
operatingMargins 0.136940
trailingEps 37.160000
forwardEps 42.480000

Glenmark Pharmaceuticals Limited's current ratio of 1.558 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects Glenmark Pharmaceuticals Limited's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
GLENMARK's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
Glenmark Pharmaceuticals Limited's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
GLENMARK's low earnings and revenue growth indicate potential profit shrinkage. This suggests that the company's financial performance may be weakening, raising concerns about its future profitability and overall business outlook.
Glenmark Pharmaceuticals Limited's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights Glenmark Pharmaceuticals Limited's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

The price of GLENMARK has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


Analysts have shown a buy bias for GLENMARK, marking it as a favorable investment option. This could inspire investors to see GLENMARK as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.